Pulmonary function and survival one year after dupilumab treatment of acute moderate to severe COVID-19: A follow up study from a Phase IIa trial

BACKGROUND: We previously conducted a Phase IIa randomized placebo-controlled trial of 40 subjects to assess the efficacy and safety of dupilumab use in those hospitalized with COVID-19 (NCT04920916). Based on our pre-clinical data suggesting downstream pulmonary dysfunction with COVID-19 induced ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendrick, Jennifer, Ma, Jennie Z., Haughey, Heather M., Coleman, Rachael, Nayak, Uma, Kadl, Alexandra, Sturek, Jeffrey M., Jackson, Patrick, Young, Mary K., Allen, Judith E., Petri, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491385/
https://www.ncbi.nlm.nih.gov/pubmed/37693596
http://dx.doi.org/10.1101/2023.09.01.23293947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491385/
https://www.ncbi.nlm.nih.gov/pubmed/37693596
http://dx.doi.org/10.1101/2023.09.01.23293947

Ejemplares similares